References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
- DestaZWardBASoukhovaNVFlockhartDAComprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6J Pharmacol Exp Ther200431031062107515159443
- HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer20099857658619629072
- GoetzMPSchaidDJWickerhamDLEvaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsClin Cancer Res201117216944695121880792
- RaeJMDrurySHayesDFATAC trialistsCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst2012104645246022395643
- ReganMMLeyland-JonesBBouzykMBreast International Group (BIG) 1–98 Collaborative GroupCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trialJ Natl Cancer Inst2012104644145122395644
- BrooksJDTeraokaSNMaloneKEWECARE Study Collaborative GroupBernsteinJLFigueiredoJCVariants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE studyInt J Mol Epidemiol Genet201341354823565321
- ManiCGelboinHVParkSSPearceRParkinsonAKupferDMetabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylationDrug Metab Dispos19932146456568104124
- IusufDTeunissenSFWagenaarERosingHBeijnenJHSchinkelAHP-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetrationJ Pharmacol Exp Ther2011337371071721378205
- ChoiHKYangJWRohSHHanCYKangKWInduction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cellsEndocr Relat Cancer200714229330317639045
- DaiDTangJRoseRIdentification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifosJ Pharmacol Exp Ther2001299382583111714865
- HustertEHaberlMBurkOThe genetic determinants of the CYP3A5 polymorphismPharmacogenetics200111977377911740341
- HesselinkDAvan SchaikRHvan der HeidenIPGenetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusClin Pharmacol Ther200374324525412966368
- HaenischSZimmermannUDazertEInfuence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortexPharmacogenomics J200771566516788565
- Kimchi-SarfatyCOhJMKimIWA “silent” polymorphism in the MDR1 gene changes substrate specificityScience2007315581152552817185560
- ChoiJHAhnBMYiJMRP2 haplotypes confer differential susceptibility to toxic liver injuryPharmacogenet Genomics200717640341517502832
- LaecheltSTurriniERuehmkorfASiegmundWCascorbiIHaenischSImpact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and functionPharmacogenomics J2011111253420351751
- SchrothWHamannUFaschingPACYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratifcationClin Cancer Res201016174468447720515869
- MadlenskyLNatarajanLTchuSTamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomesClin Pharmacol Ther201189571872521430657
- XuYSunYYa oLAssociation between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnn Oncol20081981423142918407954
- KiyotaniKMushirodaTImamuraCKSignificant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patientsJ Clin Oncol20102881287129320124171
- ParkHSChoiJYLeeMJAssociation between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatmentJ Korean Med Sci20112681007101321860550
- ToyamaTYamashitaHSugiuraHKondoNIwaseHFujiiYNo association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatmentJpn J Clin Oncol2009391065165619596663
- SukasemCSirachainanEChamnanphonMImpact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in ThailandAsian Pac J Cancer Prev20121394549455323167378
- ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmgenomics Pers Med20136374823776391
- OkishiroMTaguchiTJin KimSShimazuKTamakiYNoguchiSGenetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifenCancer2009115595296119156902
- SchrothWAntoniadouLFritzPBreast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesJ Clin Oncol200725335187519318024866
- ZhouQYuXShuCAnalysis of CYP3A4 genetic polymorphisms in Han ChineseJ Hum Genet201156641542221412247
- SupanyaDTassaneeyakulWSirivongsDPrevalence of CYP3A5 polymorphism in a Thai populationThai Journal of Pharmacology20093119597
- LimJSLChenXASinghOImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharma-cokinetics in Asian breast cancer patientsBr J Clin Pharmacol201171573775021480951
- JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
- MurdterTESchrothWBacchus-GerybadzeLGerman Tamoxifen and AI Clinicians GroupEichelbaumMSchwabMBrauchHActivity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaClin Pharmacol Ther201189570871721451508
- GoetzMRaeJSumanVPharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesJ Clin Oncol200523369312931816361630
- TuckerANTkaczukKALewisLMTomicDLimCKFlawsJAPolymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patientsCancer Lett20052171617215596297
- GjerdeJGeislerJLundgrenSAssociations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerBMC Cancer201010131320565970
- MugunduGMSallansLGuoYShaughnessyEADesaiPBAssessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomesDrug Metab Dispos201240238939622096084
- RooneyPHTelferCMcFadyenMCMelvinWTMurrayGIThe role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directionsCurr Cancer Drug Targets20044325726515134533
- MurrayGIPatimallaSStewartKNMillerIDHeysSDProfiling the expression of cytochrome P450 in breast cancerHistopathology201057220221120716162
- BaldisseraVDde MattosAACoralGPEvaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinomaAnn Hepatol201211689990623109454
- KafkaASauerGJaegerCPolymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancerInt J Oncol20032251117112112684679
- ChangHRhaSYJeungH-CAssociation of the ABCB1 gene polymorphisms 2677G.T/A and 3435C.T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patientsAnn Oncol200920227227718836089
- IllmerTSchulerUSThiedeCMDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patientsCancer Res200262174955496212208746